Physician profile
Danny T Phu
NPI 1518164094
$1,983.80
in general payments reported to CMS, 2019-2025
22 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $83.86 · 2021: $14.70 · 2022: $394 · 2023: $447 · 2024: $618 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.18 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223.25 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $210.09 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.69 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $155.32 | 2023-2025 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $148.39 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $128.48 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $102.11 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $101.52 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $95.55 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $95.55 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $93.31 | 2020-2024 | Nexletol, Contrave, Onzetra Xsail |
| Amgen INC. | $85.72 | 2020-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.69 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $53.87 | 2019 | |
| Acerus Pharmaceuticals Corporation | $45.96 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.65 | 2022 | |
| Bausch Health US, LLC | $38.89 | 2024 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $27.50 | 2023 | Jynarque |
| Biohaven Pharmaceutical Holding Company LTD. | $25.94 | 2022 | |
| Lucid Diagnostics INC. | $21.64 | 2024 | |
| Mannkind Corporation | $17.50 | 2022 | |
| Boston Scientific Corporation | $16.18 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Phu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.